Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yong Seong | - |
dc.contributor.author | Kim, Seong Hwan | - |
dc.contributor.author | Tae, Jong Hyun | - |
dc.contributor.author | Chang, In Ho | - |
dc.contributor.author | Kim, Tae-Hyoung | - |
dc.contributor.author | Myung, Soon Chul | - |
dc.contributor.author | Kim, Myoungsuk | - |
dc.contributor.author | Nguyen, Tuan Thanh | - |
dc.contributor.author | Choi, Joongwon | - |
dc.contributor.author | Kim, Jung Hoon | - |
dc.contributor.author | Kim, Jin Wook | - |
dc.contributor.author | Choi, Se Young | - |
dc.date.accessioned | 2024-01-09T08:33:16Z | - |
dc.date.available | 2024-01-09T08:33:16Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 2287-8882 | - |
dc.identifier.issn | 2287-903X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/70163 | - |
dc.description.abstract | Background: Multiple oral chemotherapeutic agents for metastatic hormone-sensitive prostate cancer (mHSPC) have been developed for conjugated use with conventional androgen deprivation therapy (ADT). Several randomized controlled trials (RCTs) report significant benefits in mHSPC patients. Therefore, we compared overall survival (OS) and progression-free survival (PFS) benefits among considerable mHSPC oral chemotherapeutic agents. Materials and methods: We investigated mHSPC treatment efficacy through a systematic RCT-trial literature review (PubMed, Embase, Web of Science, the Cochrane Library, and Scopus). Two reviewers independently screened, extracted data, and assessed bias risk in duplicate. Results: We identified 18 RCTs (n = 13,509). Concerning OS, ADT + abiraterone, ADT + abiraterone + docetaxel, ADT + apalutamide, ADT + bicalutamide, ADT + darolutamide + docetaxel, ADT + enzalutamide, ADT + orteronel, and ADT + rezvilutamide were more effective than the standard of care (SOC). Comparing PFS, most treatments were more effective than SOC, excluding ADT + bicalutamide, nilutamide, flutamide, ADT + bicalutamide + palbociclib, and ADT + nilutamide. ADT + docetaxel with androgen receptor targeted agent (ARTA) triplet therapy was not among the top three treatments determined through ranking analysis. Conclusions: Novel oral chemotherapeutic agent combination therapies must replace current ADT monotherapy and ADT + docetaxel SOC. Even so, ADT + docetaxel with ARTA triplet therapy still is not the best mHSPC treatment and requires further study. © 2023 The Asian Pacific Prostate Society | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.prnil.2023.06.003 | - |
dc.identifier.bibliographicCitation | Prostate International, v.11, no.3, pp 159 - 166 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001080169400001 | - |
dc.identifier.scopusid | 2-s2.0-85165959272 | - |
dc.citation.endPage | 166 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 159 | - |
dc.citation.title | Prostate International | - |
dc.citation.volume | 11 | - |
dc.type.docType | Article; Early Access | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Castration-sensitive | - |
dc.subject.keywordAuthor | Combination therapy | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
dc.subject.keywordAuthor | Systematic review | - |
dc.subject.keywordAuthor | Triplet therapy | - |
dc.subject.keywordPlus | COMBINED ANDROGEN BLOCKADE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | DEPRIVATION THERAPY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | BICALUTAMIDE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | FLUTAMIDE | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.